Phylogica (ASX:PYC) has patented an improvement to its Phylomer peptide platform that will allow more efficient screening of its library of billions of naturally occurring peptides and identify those with the highest potential to target disease proteins inside the cells.
To develop a new generation of therapies, the peptides need to be able to deliver biologics drugs to cells where most targets are. To do this effectively, they need to penetrate natural cell membranes; target particular parts of the cell such as nuclei and ensure that drug cargos are not trapped in endosomes.
There is a significant requirement for technologies that improve the efficiency of the delivery of large therapeutic molecules such as proteins into cells as cell membranes can be major impediments.
Phylogica’s Endosomal Escape Trap enables the efficient identification of Phylomer cell-penetrating peptide-drug conjugates that not only deliver the therapeutic payload across the cell membrane, but also efficiently escape from the endosome so that the drug can have a therapeutic effect.
It is partnering with Genentech, a member of Roche Group (VTR:ROG); MedImmune- the biologics arm of AstraZeneca (LON:AZN); Pfizer and Janssen Biotech.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.